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β-catenin signaling is a major oncogenic pathway in hepatocellular carcinoma (HCC). Since
β-catenin phosphorylation by glycogen synthase kinase 3β (GSK3β) and casein kinase 1ε
(CK1ε) results in its degradation, mutations affecting these phosphorylation sites cause β-
catenin stabilization. However, the relevance of missense mutations in non-phosphorylation
sites in exon 3 remains unclear. The current study explores significance of such mutations
in addition to addressing the clinical and biological implications of β-catenin activation in
human HCC.
Methods
Gene alteration in exon3 of CTNNB1, gene expression of β-catenin targets such as gluta-
mate synthetase (GS), axin2, lect2 and regucalcin (RGN), and protein expression of β-cate-
nin were examined in 125 human HCC tissues.
Results
Sixteen patients (12.8%) showed conventional missense mutations affecting codons 33,
37, 41, and 45. Fifteen additional patients (12.0%) had other missense mutations in codon
32, 34, and 35. Induction of exon3 mutation caused described β-catenin target gene upre-
gulation in HCC cell line. Interestingly, conventional and non-phosphorylation site mutations
were equally associated with upregulation of β-catenin target genes. Nuclear localization of
β-catenin was associated with poor overall survival (p = 0.0461). Of these patients with
nuclear β-catenin localization, loss of described β-catenin target gene upregulation showed
significant poorer overall survival than others (p = 0.0001).
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Conclusion
This study suggests that both conventional and other missense mutations in exon 3 of
CTNNB1 lead to β-catenin activation in human HCC. Additionally, the mechanism of
nuclear β-catenin localization without upregulation of described β-catenin target genes
might be of clinical importance depending on distinct mechanism.
Introduction
Primary liver cancer which is predominantly hepatocellular carcinoma (HCC), is the sixth
most common cancer worldwide and the third most frequent cause of cancer-related mortality
[1]. β-Catenin gene (CTNNB1) mutation and mutation in AXIN1 are major oncogenic gene
alterations in HCC, seen in 20–40% and 10%, respectively [2]. CTNNB1mutations cause stabi-
lization of β-catenin protein through loss of codon 33, 37, 41, and 45 phosphorylation sites for
glycogen synthase kinase 3β (GSK3β) and casein kinase 1ε (CK1ε) resulting in upregulation of
β-catenin target genes such as glutamine synthetase (GS), axin2 and regucalcin [3–6].
In addition to mutations directly affecting phosphorylation sites, there are a substantial num-
ber of patients who have other missense mutation sites in exon 3 (codon 32, 34, 35, and 36) [7].
These mutations in CTNNB1 exon 3 are theoretically considered to affect β-catenin signaling
because of the structural change of protein caused by alteration of amino acid close to the GSK3β
binding. Austinat et al. reported that transfection of P44A or H36P, mutants of CTNNB1 that are
not direct phosphorylation sites of CK1ε or GSK3β enhanced the promotor activity of TCF4/β-
catenin [8]. However, this has not been investigated directly in HCC patients.
In the current study we validate that missense mutations not directly affecting GSK3β or CKε
binding sites in β-catenin gene indeed show active β-catenin signaling in human HCC. We also
show that those HCC that exhibit nuclear β-catenin localization have worse prognosis. Immuno-
histochemical and transcriptomic analysis revealed that some patients whose tumor showed
nuclear β-catenin localization but didn’t have determined target gene upregulation turned out to
show the poorest survival. We eventually discuss the implication of targeting β-catenin signaling
in patients with aberrant β-catenin activation in HCC caused by genetic alterations [9, 10].
Materials and Methods
Clinical Tissue Samples
One hundred twenty five patients with HCC were registered and underwent curative first-line
surgery at the Department of Gastroenterological Surgery, Kumamoto University Hospital,
between 2005 and 2010. Specimens of primary HCC and adjacent normal liver tissues were
obtained from the patients after their written informed consent was obtained. This study was
approved by the Human Ethics Review Committee of the Graduate School of Life Sciences,
Kumamoto University (Kumamoto, Japan).
RNA Extraction and Quantitative Reverse Transcriptase-Polymerase
Chain Reaction (qRT-PCR)
RNA extraction, reverse transcription, and qRT-PCR was performed as previously described
[11]. Primers were designed using the Roche webpage and the Universal Probe Library in
accordance with the manufacturer’s recommendations. The primers used were as follows:
Axin2 forward 50- GCTGACGGATGATTCCATGT -30, Axin2 reverse 50- ACTGCCCACAC
GATAAGGAG -30, and universal probe #56; Lect2 forward 50- GCTATCCATGGAATATTA
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GAACTTGA -30, Lect2 reverse 50- TGCATCTCTCATTTCTTTAGTGTGA -30, and universal
probe #58; Regucalcin forward 50- TCAATGATGGGAAGGTGGAT -30, Regucalcin reverse
50- TGGTGCCGCTCAAGAACT -30, and universal probe #30; GS forward 50- AAGAGCGGA
GCGTGTGAG -30, GS reverse 50- TCATGGTGGAAGGTGTTCTG -30, and universal probe
#55; HPRT forward 50-TGACCTTGATTTATTTTGCATACC-30, HPRT reverse 50- CGAGC
AAGACGTTCAGTCCT-30, and universal probe #73. HPRT was used as internal control gene.
For amplification, an initial denaturation at 95°C for 10 min was followed by 15 s at 95°C, 15 s
at 60°C, and 13 s at 72°C.
DNA extraction and Direct sequencing
Genomic DNA was extracted using QIAamp DNAMicro Kit (Qiagen). Amplification exon 3
of CTNNB1, extraction of PCR products, and sequencing are performed as previously
described [12].
Immunocytochemistry
Cultured cells were washed, and fixed in 4% paraformaldehyde for 15 min. Subsequently, the
samples were washed and nonspecific protein binding sites were blocked by 30 min incubation
in 3% bovine serum albumin. Sections were incubated for 1 h with rabbit anti-β-catenin anti-
body (SantaCruz). After 3 washes in PBS, the sections were incubated for 30 min at room tem-
perature in the dark, with the appropriate secondary antibody. After 2 washes in PBS, Hoechst
staining was performed and the mounting reagent was applied.
Luciferase Assay
Hep3B-S33Y and Hep3B-pCI cells were plated in 24 well plate. TCF4 reporter plasmid was
transfected with lipofectamin 2000 (Invitrogen) into them. Cells were lysed and prepared by
using the luciferase reporter assay system (Promega, Madison, WI). Activity was read on a
luminometer (Lumat; EG & G Berthold).
Statistical Analysis
Statistical analyses were performed using JMP ver. 8.0 (SAS Institute., Cary, NC, USA). Values
are expressed as the mean ± SD. Differences between groups were calculated by the Wilcoxon
test. P< 0.05 was defined as significant.
Results
Gene alterations in exon 3 of CTNNB1
Direct sequencing analysis of exon3 of CTNNB1 revealed 16 patients with conventional mis-
sense mutations in the GSK3β and CK1ε phosphorylation sites affecting codons 33, 37, 41, and
45. Additional 15 patients showed mutations affecting neighboring codons that were not direct
phosphorylation sites. Thus overall, 31 (26.9%) patients had CTNNB1mutations exon 3, which
included transitions, transversions, and two very short deletions affecting codon 33 (S1 Fig and
S1 Table).
β-Catenin target gene expressions are regulated by CTNNB1 mutation
in human HCC cell line
Since we previously demonstrated gene candidates which β-catenin directly regulates in mouse
liver [13]. Among those candidates, we picked up 4 genes such as Axin2, Regucalcin, Lect2 and
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GS. To confirm that those genes are regulated by CTNNB1mutation in human HCC, we estab-
lished stable cell line expressing mutant β-catenin (S33Y) using Hep3B cell line. Hep3B trans-
fected with S33Y (Hep3B-S33Y) shows nuclear translocation of β-catenin (Fig 1A) and higher
TCF4 activity than control cell line, Hep3B-pCI (Fig 1B). Hep3B-pCI showed membraneous β-
catenin expression without nuclear translocation. Hep3B-S33Y expressed higher GS, Regucal-
cin, and Lect2 level as compared to Hep3B-pCI, suggesting that these genes are indeed upregu-
lated by CTNNB1mutation in human cell line (Fig 1C).
Relationship between CTNNB1 mutations and β-Catenin target gene
expressions
To assess the β-catenin activation in human HCC tumors displaying all CTNNB1mutations,
we examined any co-expression of surrogate Wnt target genes such as Axin2, Regucalcin, Lect2
and GS using qRT-PCR. Indeed GS expression, which is the most reliable target of β-catenin
signaling, is significantly correlated with Axin2 (p<0.0001), Lect2 (p = 0.0009), and regucarcin
Fig 1. Regulation of β-catenin target genes byCTNNB1 exon3mutation in human HCC cell line. A.
Stable cell line expressingCTNNB1 exon3 mutation (Hep3B-S33Y) is established. Control cell line is shown
as Hep3B-pCI. Immunofluorescent staining is performed with β-catenin antibody. Nuclear staining is
performed with Hoechst33342. Arrow heads show nuclear translocation of β-Catenin. B. TOP-Flash activity
is compared between Hep3B-S33Y and Hep3B-pCI. C. β-catenin target protein expressions (GS, Regucalcin
and Lect2) of Hep3B-S33Y and Hep3B-pCI are shown byWestern blot.
doi:10.1371/journal.pone.0152695.g001
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(p<0.0001) expressions (Fig 2A). Due to known heterogeneity in Wnt signaling in HCC, and
with the cut-off value as median value for each gene, we labeled HCC as β-catenin target gene
upregulation only if 2 out of 4 Wnt target genes were simultaneously upregulated. Such analy-
sis allowed us to broadly stratify patients into four groups; (1) patients with conventional
CTNNB1mutations in phosphorylation sites in exon 3 (group C); (2) patients with other non-
phosphorylation site CTNNB1mutations in exon 3 (group O); (3) patients with wild-type
CTNNB1 but β-catenin target gene upregulation (group NU); and (4) patients with wild-type
CTNNB1 and no activation of β-catenin signaling (group N) (Fig 2B). Intriguingly, almost sim-
ilar numbers of patients in group C and group O showed active β-catenin signaling (93.8% ver-
sus 86.7%), when combined and compared to the rest of HCC patients, rate of β-catenin target
gene upregulation in patients who have CTNNB1mutations (n = 31) is significantly higher
than patients without them (n = 94) (Fig 2C). We also compared expression of each of the four
Fig 2. β-catenin signaling based on target gene expressions in human HCC. A. Correlations of β-catenin target gene expressions. B. Heat map is shown
based on β-catenin target gene expressions. Patients were classified into 4 groups; patients with conventional mutations (C); patients with other site
mutations (O); patients with β-catenin target gene upregulation but no-mutation (NA); patients without mutation or signal activation (N). C. Percentage of β-
catenin signal activation is compared among three groups, HCC patients with conventional mutation, patients with other site mutation, and patients without
mutations. *p < 0.05. D. quantitative expressions of β-catenin targets,GS, Axin2, Lect2, and Regucalcin, are shown. *, p < 0.05. **, p < 0.01.
doi:10.1371/journal.pone.0152695.g002
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target genes among the four groups. Patients in group N had significantly lower expression of
all 4 β-catenin target genes as compared to all other groups (Fig 2D). GS expression in group C
was significantly higher than that in group NU and group N. Taken together, gene expression
analysis revealed that all exon 3 mutations have remarkable β-catenin activation, and some
additional patients without CTNNB1mutations also have β-catenin target gene upregulation.
Clinical relevance of β-catenin activation
Previous studies regarding immunohistological evaluation of β-catenin activation using expres-
sion of GS which is a well-known target of β-catenin suggested that not only HCC with
CTNNB1mutations but also others without such mutations showed GS overexpression. We
aimed to assess β-catenin activation in the two-sided ways by immunohistochemical analysis
forcusing on nuclear translocation of β-catenin and by qRT-PCR analysis forcusing on down-
stream target gene upregulation. Nuclear translocation of β-catenin was seen in 28 patients
(22.4%) (Fig 3A and S3 Table). The percentage of nuclear β-catenin translocation was higher
in mutated group C and O than non-mutated group NU and N (Fig 3B). Target gene upregula-
tion was 100% seen in patients with β-catenin translocation except for group N where β-cate-
nin translocation was clearly appreciated without downstream described gene upregulation,
suggesting that the function of β-catenin is distinct in the group N (Fig 3C). Collecting these
clinical observations, some patients in the group N show the distinct role of β-catenin regulat-
ing undetermined target genes (Fig 1D).
Impact of β-catenin activation on prognosis
Next, we questioned if there were any correlations between aberrant β-catenin signaling and
clinical parameters of HCC patients. We compared clinicopathological background of patients
in the four groups (S2 Table). There were no significant differences between groups except for
high tumor stage evident in the CTNNB1 other mutation group (p = 0.0164). Since there were
many patients in our prospective database who received repeated treatments, we only analyzed
patients who underwent curative surgery as an initial treatment for HCC in order to more
meaningfully determine the prognostic impact of β-catenin signaling. This group of patients
showed five year survival rate of 69.1%. There was no difference in prognosis between patients
with HCC harboring wild-type or mutated β-catenin gene (p = 0.2855). Given the previous
reports suggesting that GS expression is a good prognostic indicator [14], we first stratified
patients based on β-catenin activation as reflected by nuclear β-catenin translocation. Of note,
patients with nuclear β-catenin translocation showed significantly worse overall survival than
patients without it (p = 0.0461) in the current dataset (Fig 4A). Since we found that some
patients with nuclear β-catenin translocation are independent of known β-catenin target gene
expression, survival analysis was performed only in patients with nuclear β-catenin transloca-
tion. Intriguingly, patients without determined target gene upregulation showed remarkably
worse survival than others (p = 0.0001), suggesting that β-catenin of which function is still
undetermined in the current study might have a distinct oncogenic role in this subgroup.
Discussion
The current study was focused on β-catenin signaling in HCC in clinical settings. We demon-
strated that CTNNB1 exon3 missense mutations not directly affecting phosphorylation sites
but adjacent non-phosphorylation codons, have an equally robust effect on β-catenin activa-
tion in HCC patients. Gene expression analyses revealed that β-catenin target gene expressions
were remarkably similar in these two groups of HCC. Additionally, we reaffirm the existence of
a subset where β-catenin signaling is active in absence of CTNNB1mutations.
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We aimed to determine the significance of mutations in exon 3 of β-catenin gene that did
not directly affect a phosphorylation site. Indeed in vitro studies have previously addressed the
function of some of these mutations [8]. However, no clinical study has directly tested the rele-
vance of these mutations. We show that such mutations indeed activate β-catenin perhaps due
to effect on key recognition motifs disallowing binding of kinases such as GSK3β and CK1ε.
We found around 50% of all β-catenin mutations to be non-phosphorylation site specific as
compared to some previous studies that identified only 33% of patients with β-catenin gene
mutations to be of this kind [7].
According to previous observations, the phenotype of β-catenin mutated tumor is mutually
exclusive to p53 mutation and characterized by low rate of loss of heterozygosity, less fibrosis
Fig 3. β-catenin signaling assessed by protein expression in human HCC. A. Representative pictures for β-catenin expression in human. B. Occurrence
of β-catenin nuclear translocation in each group is shown. C. In patients with β-catenin nuclear translocation (n = 28), occurrence of β-catenin target gene
upregulation in each group is shown. D. Patients with β-catenin nuclear translocation in tumor could be divided into two groups; patients withCTNNB1
mutation and without it. Furthermore, patients withoutCTNNB1mutation were classified into two subgroups; patients with determined β-catenin target gene
upregulation and patients without it.
doi:10.1371/journal.pone.0152695.g003
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in tumor, lacking steatosis, well-differentiated tumor type, and cholestasis [3, 15–17]. More-
over, patients with β-catenin mutated tumors show better prognosis [7, 14]. Our current study
did not show any differences in prognosis when patients with mutations in exon 3 of CTNNB1
were compared to the rest. Instead, when patients were divided into group with or without
nuclear β-catenin translocation, the patients with nuclear β-catenin translocation showed a
worse overall survival. Among these patients, we unexpectedly found that some patients
completely lost described β-catenin target gene upregulation and showed the poorest overall
survival. Hoshida et al. recommended that Wnt-TGF-β subclass could be discriminated from
CTNNB1 subclass which contained CTNNB1-mutation-signature. In Wnt-TGF-β subclass,
most patients showed membraneous β-catenin expression with GS overexpression, suggesting
that molecular background of patients with the poorest prognosis in the current study might
be distinct fromWnt-TGF-β subclass [18], which is our next issue to be concerned.
Aberrant β-catenin signaling in solid cancers including HCC is well known, and has been
discussed as an attractive and therapeutic target to date [9, 10, 19–21]. Preclinical studies sug-
gest that small molecule antagonists of Tcf4/β-catenin complex inhibited the growth of HepG2
cells and downregulated β-catenin target molecule expression, c-myc and cyclin D1, in vivo
[22]. However, due to other roles of Wnt signaling in liver physiology and a paradoxical
increase in chemical carcinogen-induced HCC in β-catenin conditional knockout mice, a care-
ful selection of patients will be relevant [23]. β-catenin mutated tumors should be addicted to
β-catenin signaling for tumor progression, and our study demonstrates that both conventional
and alternate mutations in exon3 can comparably activate downstream β-catenin target genes.
Previous transcriptomic analysis and our current study suggest that patients with β-Catenin
signal activation not only in those who have CTNNB1mutation but also those who don’t have
mutation are presumably candidates for β-Catenin targeted therapy [17, 18]. In addition to the
Wnt-TGF-β subclass suggested by Hoshida et al., an another genetic event activating β-Catenin
signaling independent of CTNNB1mutation is AXIN1mutation which is reported to be seen
in more than 10% of HCC patients [2]. It is conceivable that they are included in group NU.
On the other hand, patients with β-catenin nuclear translocation in the absence of known β-
Catenin target gene upregulation showed worse prognosis. The β-Catenin target of those
patients remains unexplained. In the previous reports, additional signaling pathways also can
Fig 4. Prognostic impact of β-catenin signaling in human HCC. A. Overall survival is compared between patients with β-catenin nuclear translocation in
tumor (n = 28) and patients without it (n = 78). B. Overall survival was compared between patients with described target gene upregulation (n = 22) and others
without it (n = 6) in patients with β-catenin nuclear translocation.
doi:10.1371/journal.pone.0152695.g004
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converge at β-Catenin. β-Catenin also interacts with transcription factors such as T-cell factor,
forkhead box protein O, and hypoxia inducible factor 1α to regulate the expression of target
genes [24, 25]. The targets of β-catenin and the mechanism driving tumor progression in those
patients carrying with β-catenin nuclear translocation in the absence of CTNNB1mutation are
issues of great importance to be addressed.
In conclusion, patients with CTNNB1 exon3 mutation would be desirable candidates for β-
Catenin targeted therapy irrespective of mutation cites, and the mechanism of β-Catenin acti-
vation in the remaining patients is an urgent issue to be argued. This study would be of great
help to understand the β-Catenin activation in patients with HCC.
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